Craig-Hallum analyst Matt Hewitt lowered his price target for Cambrex to $45 from $71, while reiterating a Buy rating on the shares. With the transition to ASC 606 now behind it and revenue from both the HALO and Avista acquisitions layering on, the analyst had expected FY19 to be the year that it all comes together for Cambrex. However, with the initiation of FY19 guidance below consensus, it now appears that investors may need to wait a couple of quarters for upside from recent acquisitions to show through in the numbers, he contends. Specifically, Hewitt believes the integrated sales force may take longer to reach full productivity than he previously expected.